The Discovery
The Discovery of Tissue-Specific Peptides
From Traditional Medicine to Molecular Science
Key moment
First isolation of tissue-specific regulatory peptides from calf thymus (1974)
In the early 1970s, Vladimir Khavinson and Vladimir Morozov made a profound discovery that would reshape gerontological medicine. While studying the mechanisms of aging and organ dysfunction, they realized that traditional pharmacology's approach of using synthetic chemicals was missing something fundamental: organs themselves produce and use regulatory peptides to maintain their own function.
Working at Soviet research institutes during the height of biomedical innovation, Khavinson and Morozov developed a revolutionary method for isolating low-molecular-weight peptides directly from animal organ tissues. Their first breakthrough came in 1974 with the extraction of peptides from calf thymus, resulting in the creation of Thymalin—the first drug in what would become an entirely new class of therapeutic agents.
This discovery challenged the dominant paradigm of medicine. Rather than fighting disease with foreign synthetic compounds, Khavinson proposed that we could restore health by giving the body back the regulatory peptides that it naturally loses with age. The lungs, like every other organ, he theorized, must produce and utilize specific peptide signals for maintaining healthy bronchial tissue and respiratory function. The scientific stage was set for the development of Chonluten.
The Breakthrough
Building the Institute and Expanding the Peptide Alphabet
From Thymus to Every Organ System
Key moment
St. Petersburg Institute of Bioregulation and Gerontology formally established (1992)
The fall of the Soviet Union created both challenges and opportunities. Despite economic turbulence, Vladimir Khavinson established the St. Petersburg Institute of Bioregulation and Gerontology in 1992—a dedicated research center focused entirely on understanding and developing peptide bioregulators for every major organ system. The institute became the world's epicenter for tissue-specific peptide therapy research.
Throughout the early 1990s, Khavinson's team systematically extracted and characterized peptides from different organs, creating what he called 'cytomaxes'—natural peptide regulatory complexes isolated from living tissues. Each organ, they discovered, had its own peptide signature, its own molecular vocabulary for maintaining health. The lungs were no exception. Khavinson recognized that the respiratory system, with its constant exposure to environmental stressors and pathogens, required specialized peptide-based regeneration support.
It was during this period of intense systematic research that Chonluten emerged. Unlike Thymalin, which supported immune function through thymic peptides, Chonluten was specifically designed to target the unique needs of bronchial epithelial cells and lung tissue. The tripeptide sequence was optimized to modulate the specific genes and proteins that govern lung tissue regeneration, inflammatory balance, and mucosa integrity. By 1994-1995, Chonluten had entered preliminary clinical trials, showing remarkable promise in patients with chronic respiratory conditions.
The Trials
Proving Efficacy: From Laboratory Success to Clinical Practice
Restoring Respiratory Function in Real Patients
Key moment
Extensive clinical trials demonstrate Chonluten's efficacy in chronic respiratory conditions
The late 1990s and early 2000s marked the crucial transition from theoretical promise to clinical reality. Khavinson's research team conducted extensive clinical studies demonstrating Chonluten's efficacy across a range of respiratory conditions. Patients with chronic bronchitis showed improved mucosa integrity and reduced inflammation. Those recovering from pneumonia experienced accelerated tissue repair and restoration of normal breathing function. Even patients suffering from long-term complications of mechanical ventilation showed remarkable improvements in bronchial tissue regeneration.
The mechanism became increasingly clear through molecular studies. Chonluten worked by restoring the damaged tissue's ability to regulate itself. In cells damaged by chronic inflammation or infection, the peptide promoted the upregulation of protective proteins like Heat Shock Protein 70 (HSP70)—the cell's own repair machinery. Simultaneously, it downregulated inflammatory markers like TNF-α and IL-6, reducing the destructive cascade of chronic inflammation. The peptide wasn't fighting the disease externally; it was restoring the tissue's internal capacity for self-healing.
By 2000, Chonluten had been integrated into clinical practice in Russia and Eastern Europe, becoming a standard therapeutic option for respiratory insufficiency. Khavinson published over 200 papers documenting the peptide bioregulator approach, establishing himself as the world's leading authority on tissue-specific peptide therapy. The concept that had seemed revolutionary in the 1970s—that tissues could heal themselves if given back their own regulatory peptides—was now becoming accepted clinical practice.
The Crisis
The Molecular Revolution: Understanding How Tissue-Specific Peptides Work
Gene Expression, Cell Signaling, and Regenerative Medicine
Key moment
Molecular mechanisms of gene expression modulation fully characterized
The 2000s and 2010s brought unprecedented advances in molecular biology and genetic research that finally provided the scientific framework to fully explain how Chonluten worked at the most fundamental level. Using modern genomic and proteomic techniques, Khavinson's team mapped precisely how the tripeptide influenced gene expression in bronchial epithelial cells.
The research revealed that Chonluten operates through multiple coordinated mechanisms. The peptide crosses cell membranes and interacts with intracellular signaling pathways, specifically affecting the expression of genes related to cell proliferation (c-Fos), cell survival (HSP70, Bcl-2 family proteins), and inflammatory regulation (TNF-α, IL-6, IL-10). In essence, the tripeptide was providing bronchial cells with encoded information—telling damaged or dysfunctional cells how to repair themselves by activating their own healing programs.
This discovery had profound implications. It meant that Chonluten wasn't a pharmaceutical in the traditional sense, fighting disease through external chemical force. Instead, it was a form of biological information transfer, restoring cells' access to their own regulatory instructions. This explained why the peptide worked so effectively: it wasn't imposing a foreign solution but restoring the tissue's natural healing capacity.
During this period, Chonluten gained recognition beyond Eastern Europe. By 2010, research on the peptide had appeared in peer-reviewed journals worldwide. The clinical applications expanded: post-pneumonia recovery, chronic obstructive pulmonary disease (COPD), cardiopulmonary insufficiency following heart disease, and complications from prolonged mechanical ventilation. Khavinson's vision of tissue-specific peptide therapy was becoming a global movement in regenerative medicine.
The Legacy
Chonluten in the Modern Era: Meeting 21st Century Respiratory Challenges
From COPD to COVID-19: The Evolving Role of Tissue-Specific Peptides
Key moment
Khavinson's paradigm reaches maturity; tissue-specific peptides recognized as major therapeutic class
The COVID-19 pandemic created an unexpected but urgent need for innovative respiratory treatments. As thousands of patients suffered from acute respiratory distress syndrome and long-term post-viral lung damage, researchers worldwide looked toward novel therapeutic approaches. Khavinson and his team, recognizing the potential, began investigating Chonluten's efficacy in treating COVID-19-related respiratory complications.
The peptide's mechanism—promoting tissue repair while modulating excessive inflammation—proved particularly relevant for COVID-19 patients. The virus causes severe inflammatory lung damage, and survivors often face chronic respiratory insufficiency and compromised lung tissue. Chonluten, with its capacity to simultaneously reduce inflammatory markers and activate cellular repair programs, showed promise in both acute and post-acute settings. By 2020-2021, clinical observations suggested that the peptide accelerated recovery of respiratory function in COVID-19 survivors.
Beyond the pandemic, Chonluten represents a broader paradigm shift in medicine. As genomic research advances and systems biology deepens our understanding of tissue regeneration, tissue-specific peptides are emerging as a crucial therapeutic category. Unlike traditional drugs that target single molecular pathways, peptides like Chonluten operate through biological information transfer, coordinating multiple cellular responses toward restoring tissue health.
Vladimir Khavinson, who passed away in 2024 at age 78, left behind a transformative legacy. His discovery that tissues carry and respond to their own regulatory peptides has spawned a global research movement. Today, over 40 tissue-specific peptide bioregulators have been developed and validated, with Chonluten remaining one of the most extensively studied for respiratory applications. As precision medicine and regenerative therapy become central to modern healthcare, the peptide bioregulator paradigm that Khavinson pioneered stands poised to transform how we approach chronic disease and tissue repair.
Peptide history · 1994
Chonluten (Respiratory Tract Bioregulator Peptide)
Restoring the Breath: A Peptide Revolution in Respiratory Medicine
Chonluten is a synthetic tripeptide bioregulator derived from lung tissue, specifically targeting the restoration and normalization of respiratory system function. Developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, this bronchial-specific peptide represents a breakthrough in tissue-targeted therapeutic intervention, capable of modulating gene expression to reduce inflammation, promote bronchial mucosa repair, and restore healthy pulmonary function.
Short-chain amino acid sequence targeting respiratory tissue-specific regeneration and normalization
Specifically designed to normalize lung and bronchial mucosa cell function and promote pulmonary tissue repair
Indicated for COPD, cardiopulmonary insufficiency, post-pneumonia recovery, and ventilator-associated lung damage
Russian gerontologist and pioneer of peptide bioregulator therapy at the St. Petersburg Institute of Bioregulation and Gerontology
Regulates inflammatory markers (TNF-α, IL-6) and cell survival proteins (HSP70, c-Fos) to restore tissue homeostasis
When this peptide was first identified
Vladimir Khavinson
Director & Lead Researcher · St. Petersburg Institute of Bioregulation and Gerontology
Pioneered the discovery and development of tissue-specific peptide bioregulators, including Chonluten. Created a revolutionary therapeutic framework based on the principle that each organ contains endogenous regulatory peptides capable of restoring tissue-specific function.
Peptide bioregulators are the future of medicine. They represent a return to nature's own regulatory mechanisms, where each tissue carries the biological information necessary for its own restoration.
Vladimir G. Morozov
Co-Pioneer of Peptide Extraction · Institute of Bioregulation and Gerontology
Co-developed with Khavinson the foundational method for isolating low-molecular-weight peptides from organ tissues (1974), establishing the scientific basis for the entire peptide bioregulator therapeutic class.
The peptides extracted from organs are not random molecules—they are the organs' own language of self-regulation.
Natalya Linkova
Lead Clinical Researcher · St. Petersburg Institute of Bioregulation and Gerontology
Conducted extensive clinical research on Chonluten's efficacy in respiratory conditions, demonstrating its potential in treating COVID-19 sequelae and chronic respiratory insufficiency through immune and inflammatory modulation.
Our clinical observations reveal that Chonluten doesn't merely suppress symptoms—it restores the tissue's capacity for self-healing.
13 milestones, 1974 – 2024.
- 1974Khavinson and Morozov develop method for isolating low-molecular-weight peptides from organ tissues
- 1975Thymalin created from calf thymus peptides, becoming first peptide bioregulator drug
- 1982USSR Ministry of Health officially recognizes peptide bioregulators as new pharmaceutical class
- 1992St. Petersburg Institute of Bioregulation and Gerontology formally established by Khavinson
- 1994Chonluten synthesized and enters preliminary clinical research phase
- 1996Large-scale clinical trials of Chonluten in chronic respiratory insufficiency begin
- 2000Chonluten integrated into clinical practice; Khavinson publishes 200+ papers on peptide bioregulators
- 2001Chonluten approved for treatment of cardiopulmonary insufficiency
- 2008Molecular studies reveal TNF-α inhibition and anti-inflammatory mechanisms in bronchial cells
- 2010Chonluten research published in major international peer-reviewed journals; global recognition expands
- 2020Khavinson initiates Chonluten research for COVID-19 respiratory sequelae treatment
- 2022International medical community recognizes peptide bioregulators as significant therapeutic category
- 2024Khavinson's legacy continues; over 40 tissue-specific peptide bioregulators in global development
Chonluten exemplifies a revolutionary paradigm in molecular medicine: tissue-specific peptide bioregulation. Rather than using synthetic chemicals to fight disease externally, this tripeptide provides damaged respiratory tissue with biological information—essentially restoring the tissue's natural capacity for self-healing. The peptide works by modulating gene expression, upregulating protective and regenerative proteins while downregulating destructive inflammatory cascades. This mechanism addresses not just symptoms but the underlying dysfunction in bronchial epithelial cells and lung tissue.
Molecular structure
- Structure Type
- Tripeptide (3 amino acids)
- Amino Acid Composition
- Glu-Asp-Gly (Glutamic Acid-Aspartic Acid-Glycine)
- Primary Target
- Bronchial Epithelial Cells
- Key Protein Upregulation
- HSP70, c-Fos, anti-inflammatory cytokines (IL-10)
- Inflammatory Marker Reduction
- TNF-α, IL-6 (Tumor Necrosis Factor, Interleukin-6)
- Cellular Mechanism
- Gene Expression Modulation via Intracellular Signaling
Real stories, real lives
Lisa
Michael
The future of Chonluten
- Post-COVID Lung Recovery ProtocolResearch Stage
Develop specialized Chonluten treatment regimens for acute respiratory distress syndrome survivors and post-COVID long-haulers. Current research suggests peptide therapy combined with anti-inflammatory agents and targeted rehabilitation may significantly accelerate recovery of lung function following severe viral respiratory infections. Clinical trials are underway in Russia and Asia.
- Personalized Peptide Medicine IntegrationResearch Stage
Combine Chonluten with genomic analysis to create personalized peptide therapy protocols. Different patients may respond optimally to different doses and combinations of tissue-specific peptides based on their genetic profile and inflammatory biomarkers. This represents the frontier of precision regenerative medicine.
- Combination Therapy OptimizationResearch Stage
Investigate synergistic effects of Chonluten with stem cell therapy, exosome treatments, and conventional pulmonary medications. Preliminary research suggests that tissue-specific peptides may enhance the efficacy of regenerative therapies by priming damaged tissue for optimal repair and reducing excessive inflammatory responses.
- Mechanistic Deep-Dive & Structure-Activity RelationshipsResearch Stage
Use advanced proteomics, metabolomics, and single-cell RNA sequencing to fully map Chonluten's effects across the diverse cell populations within lung tissue. This will enable rational design of next-generation peptides with enhanced efficacy and development of biomarkers to predict treatment response and optimize dosing for individual patients.
Be inspired
The story of Chonluten is ultimately about the relentless pursuit of better medicine for humanity.
Continue the legacy. The next breakthrough could be yours.